KLK3 and prostate cancer: To control for potential differences between testosterone-treated and untreated men, we performed time-varying adjustments for 26 medical comorbidities, repeat testosterone testing, and the intensity of PSA screening as these factors may have affected the likelihood of being treated with testosterone and detecting prostate cancer.